ArticleThe Lancet. Oncology2019
Refining prognosis after first-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy in chronic lymphocytic leukaemia.
Lukáš SmolejPubMed ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it